GLP-1 drugs show more benefits than risks for approved uses in new analysis

A new analysis shows that GLP-1 drugs like Ozempic and Wegovy offer more benefits than risks for approved uses, particularly in treating type 2 diabetes and obesity. The study examined health records of over 200,000 diabetes patients using these drugs. The findings indicate that users had a lower risk of 42 health conditions, including a 9% reduction in heart attack risk and an 8% decrease in dementia risk. However, users also faced higher risks for some side effects, such as kidney stones and pancreatitis. While the benefits are clear for those with diabetes and obesity, the effects for individuals without these conditions remain uncertain. Future studies are expected to provide more detailed data on specific health impacts.